Theralase Technologies Inc
XTSX:TLT

Watchlist Manager
Theralase Technologies Inc Logo
Theralase Technologies Inc
XTSX:TLT
Watchlist
Price: 0.26 CAD Market Closed
Market Cap: 63.1m CAD
Have any thoughts about
Theralase Technologies Inc?
Write Note

Theralase Technologies Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Theralase Technologies Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Theralase Technologies Inc
XTSX:TLT
Income from Continuing Operations
-CA$4.4m
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
-12%
Titan Medical Inc
TSX:TMD
Income from Continuing Operations
-$5m
CAGR 3-Years
49%
CAGR 5-Years
39%
CAGR 10-Years
10%
Profound Medical Corp
TSX:PRN
Income from Continuing Operations
-$31.4m
CAGR 3-Years
-4%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Income from Continuing Operations
-CA$12.4m
CAGR 3-Years
-67%
CAGR 5-Years
-22%
CAGR 10-Years
-18%
MedMira Inc
XTSX:MIR
Income from Continuing Operations
-CA$3.3m
CAGR 3-Years
-70%
CAGR 5-Years
-10%
CAGR 10-Years
1%
O
Ondine Biomedical Inc
LSE:OBI
Income from Continuing Operations
-CA$14.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Theralase Technologies Inc
Glance View

Market Cap
62.2m CAD
Industry
Health Care

Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.

TLT Intrinsic Value
0.92 CAD
Undervaluation 72%
Intrinsic Value
Price

See Also

What is Theralase Technologies Inc's Income from Continuing Operations?
Income from Continuing Operations
-4.4m CAD

Based on the financial report for Jun 30, 2024, Theralase Technologies Inc's Income from Continuing Operations amounts to -4.4m CAD.

What is Theralase Technologies Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-12%

Over the last year, the Income from Continuing Operations growth was 9%.

Back to Top